The modern healthcare system is suffering from a malignant condition, but it is not one found in any medical textbook. It is a systemic pathology where a fiduciary duty to shareholders has quietly superseded the Hippocratic Oath. In this landscape, the patient is no longer the priority; they are merely the raw material from which profit is extracted. The noble goal of healing the sick has been relegated to the tail end of the priority list, far behind the primary objectives of quarterly earnings, executive bonuses, and the relentless demand to increase stock prices.
At the heart of this dysfunction lies the pharmaceutical industry, a sector that frequently spends more on marketing and advertising than on research and development. The narrative sold to the public is one of tireless innovation and life-saving breakthroughs, but the reality is often a business model built on patent manipulation and price gouging. Companies routinely engage in “evergreening,” a practice where they make trivial modifications to existing drugs—not to improve patient outcomes, but to reset the patent clock and maintain a monopoly that blocks cheaper generic alternatives. This ensures that the flow of revenue remains uninterrupted, regardless of the financial toxicity it inflicts on patients struggling to afford basic survival.
This corruption extends deep into the scientific process itself, particularly in clinical trials. This is where “the Delta”—the statistical gap between a drug’s performance and a placebo—is weaponised. In an honest system, trials would be designed to prove that a new drug is significantly better than the existing, cheaper standard of care. Instead, trials are often engineered to yield results that are just statistically significant enough to gain FDA approval, even if the clinical benefit to the patient is negligible. A drug might offer a “delta” of improvement that is mathematically measurable but practically useless. Yet this slight variation is used to justify a price tag thousands of dollars higher than the older medication.
The rot has spread beyond the manufacturers and deeply infected the very institutions designed to validate truth: medical publishing and academic research. The prestigious medical journals, once viewed as the incorruptible gatekeepers of science, have increasingly become marketing arms for the industry. A significant portion of journal revenue comes from pharmaceutical advertising and the sale of “reprints”—glossy copies of favourable studies that sales reps distribute to doctors. This creates a massive conflict of interest where editors may be hesitant to publish critical findings that would alienate their biggest sponsors. Furthermore, the phenomenon of “ghostwriting” has turned research into a masquerade; pharmaceutical marketing teams frequently write articles highlighting their product’s benefits, only to pay prominent academic physicians to attach their names to the paper. The result is that what appears to be independent academic consensus is often just corporate copywriting in a lab coat.
This illusion of consensus is further cemented at medical conferences, which have transformed from forums of scientific debate into lavish trade shows designed to indoctrinate physicians. These events are dominated by “Key Opinion Leaders” (KOLs)—influential doctors who receive substantial consulting fees and speaking honoraria from drug companies. Their role is to present the industry’s data in a favourable light, normalising the use of expensive new therapies over cost-effective alternatives. Doctors attending these conferences believe they are receiving unbiased education. Still, they are effectively being steered by a curated curriculum designed to maximise prescriptions and, by extension, the company’s stock price. The “research” presented is often funded by the very entities that stand to profit, creating a closed loop in which negative data is suppressed, and positive data is amplified to satisfy investor expectations.
The betrayal is compounded by the health insurance industry, which functions as the gatekeeper of care. Unlike legitimate healthcare providers, insurance companies generate profit specifically by not providing service. Their business model relies on collecting premiums and systematically denying claims. Every procedure denied and every medication rejected directly translates into a healthier bottom line and a happier board of directors. The administrative complexity of the system is a feature, not a bug; it is designed to wear down patients and doctors through attrition until they give up on the care they are owed.
Ultimately, this entire ecosystem—from the lab bench to the medical journal to the insurance office—is driven by the demands of the stock market. Corporate executives are legally beholden to maximise shareholder value, creating a perverse incentive structure in which curing a disease is seen as a poor business model. A patient who is healed is a customer lost; a patient who is dependent on a lifelong treatment is a recurring revenue stream. As long as the medical field is tethered to the volatility of the stock market, the “care” in healthcare will remain an illusion, and the patient will remain last on the list, sacrificed on the altar of the quarterly report.